Zobrazeno 1 - 10
of 438
pro vyhledávání: '"Peter Sinn"'
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-9 (2023)
Abstract Ovarian cancer (OC) is an aggressive disease, primarily diagnosed in late stages with only 20% of patients surviving more than 5 years. Liquid biopsy markers have great potential to improve current diagnostic and prognostic methods. Here, we
Externí odkaz:
https://doaj.org/article/38343a3e1dcc4100a4c64e962d6e4d77
Autor:
Yosuke Yamada, Djeda Belharazem-Vitacolonnna, Hanibal Bohnenberger, Christel Weiß, Naoko Matsui, Mark Kriegsmann, Katharina Kriegsmann, Peter Sinn, Katja Simon-Keller, Gerhard Hamilton, Thomas Graeter, Gerhard Preissler, German Ott, Sebastian Schölch, Naoki Nakajima, Akihiko Yoshizawa, Hironori Haga, Hiroshi Date, Roman K. Thomas, Iacopo Petrini, Giuseppe Giaccone, Philipp Ströbel, Alexander Marx
Publikováno v:
Cell Death and Disease, Vol 13, Iss 11, Pp 1-11 (2022)
Abstract Tuft cells are chemosensory epithelial cells in the respiratory tract and several other organs. Recent studies revealed tuft cell-like gene expression signatures in some pulmonary adenocarcinomas, squamous cell carcinomas (SQCC), small cell
Externí odkaz:
https://doaj.org/article/aaade6c0d522458ea3d812565b5a42cc
Publikováno v:
Pathogens, Vol 12, Iss 12, p 1387 (2023)
Based on epidemiological evidence and molecular findings, a possible association of Epstein–Barr virus (EBV) with the carcinogenesis of breast cancer has been described. However, the frequency of EBV in breast cancer and the role of EBV regarding t
Externí odkaz:
https://doaj.org/article/081ec844e506497f8f597c9139c63164
Autor:
Josef Rüschoff, Annette Lebeau, Peter Sinn, Hans-Ulrich Schildhaus, Thomas Decker, Johannes Ammann, Claudia Künzel, Winfried Koch, Michael Untch
Publikováno v:
Breast, Vol 49, Iss , Pp 246-253 (2020)
Background: The German NIU HER2 model was developed based on five variables found to have statistically significant influences on HER2-positivity, to allow exploration of deviations between model-predicted and actual HER2-positivity rates as a measur
Externí odkaz:
https://doaj.org/article/031761f292f54ba593fe8d88242c9b41
Autor:
Ramona Erber, Miriam Angeloni, Robert Stöhr, Michael P. Lux, Daniel Ulbrich-Gebauer, Enrico Pelz, Agnes Bankfalvi, Kurt W. Schmid, Robert F. H. Walter, Martina Vetter, Christoph Thomssen, Doris Mayr, Frederick Klauschen, Peter Sinn, Karl Sotlar, Katharina Stering, Albrecht Stenzinger, Marius Wunderle, Peter A. Fasching, Matthias W. Beckmann, Oliver Hoffmann, Rainer Kimmig, Nadia Harbeck, Rachel Wuerstlein, Fulvia Ferrazzi, Arndt Hartmann
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 15, p 8716 (2022)
In intermediate risk hormone receptor (HR) positive, HER2 negative breast cancer (BC), the decision regarding adjuvant chemotherapy might be facilitated by multigene expression tests. In all, 142 intermediate risk BCs were investigated using the PAM5
Externí odkaz:
https://doaj.org/article/aed511032752487bac880db052f7203c
Autor:
Bernd Uhl, Laura AMittmann, Julian Dominik, Roman Hennel, Bojan Smiljanov, Florian Haring, Johanna BSchaubächer, Constanze Braun, Lena Padovan, Robert Pick, Martin Canis, Christian Schulz, Matthias Mack, Ewgenija Gutjahr, Peter Sinn, Jörg Heil, Katja Steiger, Sandip M Kanse, Wilko Weichert, Markus Sperandio, Kirsten Lauber, Fritz Krombach, Christoph A Reichel
Publikováno v:
EMBO Molecular Medicine, Vol 13, Iss 6, Pp n/a-n/a (2021)
Abstract High intratumoral levels of urokinase‐type plasminogen activator (uPA)‐plasminogen activator inhibitor‐1 (PAI‐1) heteromers predict impaired survival and treatment response in early breast cancer. The pathogenetic role of this protei
Externí odkaz:
https://doaj.org/article/4c70973c2a744ff8b94cdcdb9b282bf8
Autor:
Joerg Heil, Peter Sinn, Hannah Richter, André Pfob, Benedikt Schaefgen, André Hennigs, Fabian Riedel, Bettina Thomas, Marc Thill, Markus Hahn, Jens-Uwe Blohmer, Sherko Kuemmel, Maria Margarete Karsten, Mattea Reinisch, John Hackmann, Toralf Reimer, Geraldine Rauch, Michael Golatta
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-7 (2018)
Abstract Background Neoadjuvant chemotherapy (NACT) is a standard approach of the multidisciplinary treatment of breast cancer. Depending on the biological subtype a pathological complete response in the breast (bpCR) can be achieved in up to 60% of
Externí odkaz:
https://doaj.org/article/b30b4bcfffea4945ada3163c51894793
Autor:
Zsuzsanna Varga, Annette Lebeau, Hong Bu, Arndt Hartmann, Frederique Penault-Llorca, Elena Guerini-Rocco, Peter Schraml, Fraser Symmans, Robert Stoehr, Xiaodong Teng, Andreas Turzynski, Reinhard von Wasielewski, Claudia Gürtler, Mark Laible, Kornelia Schlombs, Heikki Joensuu, Thomas Keller, Peter Sinn, Ugur Sahin, John Bartlett, Giuseppe Viale
Publikováno v:
Breast Cancer Research, Vol 19, Iss 1, Pp 1-13 (2017)
Abstract Background Accurate determination of the predictive markers human epidermal growth factor receptor 2 (HER2/ERBB2), estrogen receptor (ER/ESR1), progesterone receptor (PgR/PGR), and marker of proliferation Ki67 (MKI67) is indispensable for th
Externí odkaz:
https://doaj.org/article/288d24888fb94127a25d598770a1c612
Autor:
Mark Kriegsmann, Christian Haag, Cleo-Aron Weis, Georg Steinbuss, Arne Warth, Christiane Zgorzelski, Thomas Muley, Hauke Winter, Martin E. Eichhorn, Florian Eichhorn, Joerg Kriegsmann, Petros Christopoulos, Michael Thomas, Mathias Witzens-Harig, Peter Sinn, Moritz von Winterfeld, Claus Peter Heussel, Felix J. F. Herth, Frederick Klauschen, Albrecht Stenzinger, Katharina Kriegsmann
Publikováno v:
Cancers, Vol 12, Iss 6, p 1604 (2020)
Reliable entity subtyping is paramount for therapy stratification in lung cancer. Morphological evaluation remains the basis for entity subtyping and directs the application of additional methods such as immunohistochemistry (IHC). The decision of wh
Externí odkaz:
https://doaj.org/article/d77f75e060c541c98e178178e8b928c4
Autor:
Stefan Stefanovic, Thomas M. Deutsch, Ralph Wirtz, Andreas Hartkopf, Peter Sinn, Maximilian Kohler, Jan Hofmann, Sanja Bankovic, Katja Vassilev, Marc Sütterlin, Andreas Schneeweiss, Markus Wallwiener
Publikováno v:
Diagnostics, Vol 10, Iss 6, p 369 (2020)
Breast cancers (BC) can mutate, allowing metastatic tumors (MT) to sometimes differ to primary tumors (PT) in gene expression. Despite contemporary metastatic breast cancer (MBC) therapy, subtype conversion seems prognostically disadvantageous. We st
Externí odkaz:
https://doaj.org/article/e572f7b7a6d6462484adf1fee813cdae